<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>526</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15102666</PubmedId>
            <Abstract>PURPOSE: We intranodally immunized metastatic colorectal carcinoma patients, who had failed standard chemotherapy, with dendritic cells (DCs) pulsed with HLA-A*0201- or HLA-A*2402-restricted carcinoembryonic antigen (CEA) peptides to evaluate the safety of this treatment and the immune response against CEA peptides before and after the treatment. EXPERIMENTAL DESIGN: We intranodally immunized metastatic colorectal carcinoma patients, who had failed standard chemotherapy, with dendritic cells (DCs) pulsed with HLA-A*0201- or HLA-A*2402-restricted carcinoembryonic antigen (CEA) peptides to evaluate the safety of this treatment and the immune response against CEA peptides before and after the treatment.Six patients with the HLA-A*2402 genotype and 4 patients with the HLA-A*0201 genotype were enrolled. A single CEA peptide (YLSGANLNL) or two CEA peptides (QYSWFVNGTF and TYACFVSNL) were used for patients with the HLA-A*0201 or HLA-A*2402 genotype, respectively. Autologous DCs were generated by culturing adherent mononuclear cells with interleukin 4 and granulocyte macrophage colony-stimulating factor for 6 days. Maturation of DCs was then induced with tumor necrosis factor alpha for 40 h. Mature DCs were pulsed with appropriate CEA peptides for 2 h. After washing, 1 million peptide-pulsed DCs were injected into one inguinal lymph node under sonographic guidance. Each patient received four injections. RESULTS: We intranodally immunized metastatic colorectal carcinoma patients, who had failed standard chemotherapy, with dendritic cells (DCs) pulsed with HLA-A*0201- or HLA-A*2402-restricted carcinoembryonic antigen (CEA) peptides to evaluate the safety of this treatment and the immune response against CEA peptides before and after the treatment.Six patients with the HLA-A*2402 genotype and 4 patients with the HLA-A*0201 genotype were enrolled. A single CEA peptide (YLSGANLNL) or two CEA peptides (QYSWFVNGTF and TYACFVSNL) were used for patients with the HLA-A*0201 or HLA-A*2402 genotype, respectively. Autologous DCs were generated by culturing adherent mononuclear cells with interleukin 4 and granulocyte macrophage colony-stimulating factor for 6 days. Maturation of DCs was then induced with tumor necrosis factor alpha for 40 h. Mature DCs were pulsed with appropriate CEA peptides for 2 h. After washing, 1 million peptide-pulsed DCs were injected into one inguinal lymph node under sonographic guidance. Each patient received four injections.No grade II/III toxicity or autoimmunity was observed. An increase in the number of CEA-specific T cells after DC vaccination could be detected in 7 of 10 (70%) patients. Two (20%) patients had stable disease for at least 12 weeks. One of these 2 patients experienced a transient decrease in CEA levels during the treatment period and also had the most significant T-cell response against the immunizing CEA peptides. CONCLUSIONS: We intranodally immunized metastatic colorectal carcinoma patients, who had failed standard chemotherapy, with dendritic cells (DCs) pulsed with HLA-A*0201- or HLA-A*2402-restricted carcinoembryonic antigen (CEA) peptides to evaluate the safety of this treatment and the immune response against CEA peptides before and after the treatment.Six patients with the HLA-A*2402 genotype and 4 patients with the HLA-A*0201 genotype were enrolled. A single CEA peptide (YLSGANLNL) or two CEA peptides (QYSWFVNGTF and TYACFVSNL) were used for patients with the HLA-A*0201 or HLA-A*2402 genotype, respectively. Autologous DCs were generated by culturing adherent mononuclear cells with interleukin 4 and granulocyte macrophage colony-stimulating factor for 6 days. Maturation of DCs was then induced with tumor necrosis factor alpha for 40 h. Mature DCs were pulsed with appropriate CEA peptides for 2 h. After washing, 1 million peptide-pulsed DCs were injected into one inguinal lymph node under s...</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>2645-51</ArticlePages>
            <ArticleTitle>Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Ko-Jiunn</ForeName>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Chuan-Cheng</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Li-Tzong</ForeName>
                </Author>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Ann-Lii</ForeName>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Dong-Tsamn</ForeName>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Yu-Chen</ForeName>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Wei-Lan</ForeName>
                </Author>
                <Author>
                    <LastName>Hung</LastName>
                    <ForeName>Yi-Mei</ForeName>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Hui-Yu</ForeName>
                </Author>
                <Author>
                    <LastName>Juang</LastName>
                    <ForeName>Shin-Hun</ForeName>
                </Author>
                <Author>
                    <LastName>Whang-Peng</LastName>
                    <ForeName>Jacqueline</ForeName>
                </Author>
            </Authors>
            <Affiliations>Cancer Research Cooperative Laboratory at the National Taiwan University Hospital, Division of Cancer Research, National Health Research Institutes, Taipei, Republic of China.</Affiliations>
            <ArticleChemicalList>Cancer Vaccines;Carcinoembryonic Antigen;HLA-A Antigens;HLA-A*02:01 antigen;HLA-A*24:02 antigen;HLA-A2 Antigen;HLA-A24 Antigen;Peptides;Interferon-gamma;Granulocyte-Macrophage Colony-Stimulating Factor</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adult; Aged; Cancer Vaccines; Carcinoembryonic Antigen(immunology); Cells, Cultured; Colorectal Neoplasms(genetics; therapy); Dendritic Cells(metabolism); Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Genotype; Granulocyte-Macrophage Colony-Stimulating Factor(metabolism); HLA-A Antigens(genetics); HLA-A2 Antigen; HLA-A24 Antigen; Humans; Immunotherapy(methods); Interferon-gamma(metabolism); Leukocytes, Mononuclear(metabolism); Male; Middle Aged; Peptides(chemistry; therapeutic use); T-Lymphocytes(immunology; metabolism); Time Factors</ArticleMeshHeadingsList>
            <Journal>
                <Volume>10</Volume>
                <Issue>8</Issue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <Issn>1078-0432</Issn>
                <MedlineTa>Clin Cancer Res</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>A*0201 peptide</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YLSGANLNL</LinearSequence>
                        <StartingPosition>605</StartingPosition>
                        <EndingPosition>613</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P06731.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 2646</LocationOfData>
                <EpitopeId>74915</EpitopeId>
                <ReferenceStartingPosition>605</ReferenceStartingPosition>
                <ReferenceEndingPosition>613</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>3591</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>46-74 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:235</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YLSGANLNL</LinearSequence>
                                            <StartingPosition>605</StartingPosition>
                                            <EndingPosition>613</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06731.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A*0201 peptide</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Target lymph node immunization</Route>
                                <DoseSchedule>Patients were vaccinated once a week for 3 weeks followed by a single booster 2 weeks later.</DoseSchedule>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Donors had metastatic colorectal carcinoma.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>A*0201 peptide</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YLSGANLNL</LinearSequence>
                                        <StartingPosition>605</StartingPosition>
                                        <EndingPosition>613</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06731.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>The authors note that the increases of CEA-specific T cells responses are minor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A</LocationOfData>
                        <TCellId>3583</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>46-74 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:235</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YLSGANLNL</LinearSequence>
                                            <StartingPosition>605</StartingPosition>
                                            <EndingPosition>613</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06731.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A*0201 peptide</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Target lymph node immunization</Route>
                                <DoseSchedule>Patients were vaccinated once a week for 3 weeks followed by a single booster 2 weeks later.</DoseSchedule>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Donors had metastatic colorectal carcinoma.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>A*0201 peptide</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YLSGANLNL</LinearSequence>
                                        <StartingPosition>605</StartingPosition>
                                        <EndingPosition>613</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06731.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>The authors note that the increases of CEA-specific T cells responses are minor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>A*2402 peptide-1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QYSWFVNGTF</LinearSequence>
                        <StartingPosition>268</StartingPosition>
                        <EndingPosition>277</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P06731.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 2647</LocationOfData>
                <EpitopeId>53036</EpitopeId>
                <ReferenceStartingPosition>268</ReferenceStartingPosition>
                <ReferenceEndingPosition>277</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <TCellId>3592</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>37-61 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:235</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>QYSWFVNGTF</LinearSequence>
                                            <StartingPosition>268</StartingPosition>
                                            <EndingPosition>277</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06731.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A*2402 peptide-1</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Target lymph node immunization</Route>
                                <DoseSchedule>Patients were vaccinated once a week for 3 weeks followed by a single booster 2 weeks later.</DoseSchedule>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Donors had metastatic colorectal carcinoma.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>A*2402 peptide-1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QYSWFVNGTF</LinearSequence>
                                        <StartingPosition>268</StartingPosition>
                                        <EndingPosition>277</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06731.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>The authors note that the increases of CEA-specific T cells responses are minor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3 and table 3</LocationOfData>
                        <TCellId>3594</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>37-61 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:235</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>QYSWFVNGTF</LinearSequence>
                                            <StartingPosition>268</StartingPosition>
                                            <EndingPosition>277</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06731.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A*2402 peptide-1</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Target lymph node immunization</Route>
                                <DoseSchedule>Patients were vaccinated once a week for 3 weeks followed by a single booster 2 weeks later.</DoseSchedule>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Donors had metastatic colorectal carcinoma.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>A*2402 peptide-1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QYSWFVNGTF</LinearSequence>
                                        <StartingPosition>268</StartingPosition>
                                        <EndingPosition>277</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06731.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>The authors note that the increases of CEA-specific T cells responses are minor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>A*2402 peptide-2</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TYACFVSNL</LinearSequence>
                        <StartingPosition>652</StartingPosition>
                        <EndingPosition>660</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P06731.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 2647</LocationOfData>
                <EpitopeId>67308</EpitopeId>
                <ReferenceStartingPosition>652</ReferenceStartingPosition>
                <ReferenceEndingPosition>660</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2C</LocationOfData>
                        <TCellId>3595</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>37-61 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:235</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TYACFVSNL</LinearSequence>
                                            <StartingPosition>652</StartingPosition>
                                            <EndingPosition>660</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06731.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A*2402 peptide-2</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Target lymph node immunization</Route>
                                <DoseSchedule>Patients were vaccinated once a week for 3 weeks followed by a single booster 2 weeks later.</DoseSchedule>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Donors had metastatic colorectal carcinoma.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>A*2402 peptide-2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYACFVSNL</LinearSequence>
                                        <StartingPosition>652</StartingPosition>
                                        <EndingPosition>660</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06731.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>The authors note that the increases of CEA-specific T cells responses are minor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3 and table 3</LocationOfData>
                        <TCellId>3596</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>37-61 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:235</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TYACFVSNL</LinearSequence>
                                            <StartingPosition>652</StartingPosition>
                                            <EndingPosition>660</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06731.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A*2402 peptide-2</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Target lymph node immunization</Route>
                                <DoseSchedule>Patients were vaccinated once a week for 3 weeks followed by a single booster 2 weeks later.</DoseSchedule>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Donors had metastatic colorectal carcinoma.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>A*2402 peptide-2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYACFVSNL</LinearSequence>
                                        <StartingPosition>652</StartingPosition>
                                        <EndingPosition>660</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06731.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>The authors note that the increases of CEA-specific T cells responses are minor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

